



10-22-94

1813-0370

10/21/94 PATENT

#6  
mjw  
11/22/94

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Serial application : Griffith et al.  
Serial No. : 08/226,248  
Filed : April 8, 1994  
Attorney Docket No. : 025.5 US  
For : ALLERGENIC PROTEINS AND PEPTIDES  
FROM JAPANESE CEDAR POLLEN

RECEIVED

JUL 19 1994

APPLICATION DIVISION

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Honorable Commissioner of Patents and Trademarks, Washington, D.C. 20231 on July 8, 1994.

By Lorraine Miller Doyle  
Lorraine Miller Doyle

INFORMATION DISCLOSURE  
STATEMENT TRANSMITTAL

Honorable Commissioner of Patents  
and Trademarks  
Washington, DC 20231

Sir:

Transmitted herewith is:

- [X] an Information Disclosure Statement  
[X] a 5-page PTO 1449 citing 25 reference(s)  
[X] also transmitted are the references cited on PTO Form 1449.

1. [X] This Information Disclosure Statement is filed before the later of:  
a. three months from the filing date of this national application;  
b. three months from the date of entry of the national stage as  
forth in 37 CFR 1.491 in an international application, or;  
c. the mailing date of a first Office Action on the merits.

In accordance with 37 CFR 1.97(b), no fee is required.

2. [ ] This Information Disclosure Statement is filed after the events  
noted in paragraph 1, but before either:  
a. a final action under 37 CFR 1.113, or  
b. a Notice of Allowance under 37 CFR 1.311.

In accordance with 37 CFR 1.97(c) also enclosed is:

- [ ] a fee under 37 CFR 1.17(p) in the amount of \$200.00; or  
[ ] a certification as stated below.

GROUP 1800

RECEIVED  
NOV 21 1994  
GROUP 1800

3. ☐ This Information Disclosure Statement is filed before the payment of the issue fee, but after either:

- a. a final action under 37 CFR 1.113, or
- b. a Notice of Allowance under 37 CFR 1.311.

In accordance with 37 CFR 1.97(d) also enclosed is:

- a. a certification, as stated below;
- b. a Petition requesting consideration of the Information Disclosure Statement, and
- c. the Petition fee set forth in 37 CFR 1.17(i)(I) in the amount of \$130.00.

Certification

The undersigned also states:

- ☐ Each item of information contained in the Information Disclosure Statement cited herein was cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing date of this Information Disclosure Statement; or
- ☐ No item of information contained in the Information Disclosure Statement submitted herewith was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing date of this Information Disclosure Statement.

The fees indicated above are:

TOTAL FEES: \$0


☐ Please charge Deposit Account No. 09-0087 in the amount of \$\_\_\_\_\_

☒ No fee is required.

☒ The Commissioner is hereby authorized to charge any underpayment of any fees associated with this communication, including any necessary fees for extension of time, or credit any overpayment to Deposit Account No. 09-0087.

This form is being **submitted in triplicate** for accounting purposes.

Respectfully submitted,

  
Darlene A. Vanstone, Reg. No. 35,729  
Attorney for Applicants  
Date: July 8, 1994  
ImmuLogic Pharmaceutical Corporation  
610 Lincoln Street, Waltham, MA 02154  
Telephone: 617-494-0060